Access links:
CONTENT
Destacados
-
A randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
Angus, B., Lampe, F., Tambussi, G., Duvivier, C., Katlama, C., Youle, M., Williams, I., Clotet, B., Fisher, M., Post, F. A., et al.AIDS. 2008 Mar 30;22(6):737-40.
-
Potencial de los inhibidores de la integrasa para deplecionar los reservorios o para impedir que se rellenen
Llibre, J.M., Martínez-Picado, J.Enfer Infecc Microbiol Clin 12: 17-22
-
Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026
Moncunill, G., Armand-Ugon, M., Clotet-Codina, I., Pauls, E., Ballana, E., Llano, A., Romagnoli, B., Vrijbloed, J. W., Gombert, F. O., Clotet, B., et al.Mol Pharmacol 73, 1264-1273
-
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.HIV Clin Trials 9, 177-85.
